Abdul Alchaki, MD
Neurology · Houston, TXNPI 1821418666
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,801 of the $116,272 with a category attached, or 79.8%. 20 manufacturers reported payments, led by EMD Serono, Inc. at 52.0% of the total. 2025 is the largest year on record at $99,589, more than ten times the $492 reported in 2019. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $445.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$60K
- TG Therapeutics, Inc.$44K
- Amgen$9K
- Biogen$806
- Novartis$562
- AstraZeneca$522
- plus $989 from 14 others
Across 4 payments — averaging $7509.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$30K
- E.r. Squibb & Sons, L.L.C.$77
What the payments were for
- Consulting fees$7,0636%
- Speaking & faculty fees$92,80180%
- Travel & lodging$8,9598%
- Food & beverage$7,1716%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 71 | $60,420 |
| TG Therapeutics, Inc. | 57 | $44,452 |
| Amgen(2 entities) | 34 | $8,520 |
| Biogen | 19 | $806 |
| Novartis | 26 | $562 |
| AstraZeneca | 11 | $522 |
| AbbVie(2 entities) | 13 | $255 |
| Pfizer | 7 | $140 |
| Bristol Myers Squibb | 6 | $134 |
| Genentech USA, Inc. | 6 | $99 |
| Genentech, Inc. | 2 | $78 |
| Acorda Therapeutics, Inc | 1 | $70 |
| Avanir Pharmaceuticals, Inc. | 1 | $69 |
| Springworks Therapeutics, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,272 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 19 | $340 |
Paid to pharmacies, not to this prescriber.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.